91 related articles for article (PubMed ID: 20036889)
61. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
62. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
63. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
Nordby Y; Andersen S; Richardsen E; Ness N; Al-Saad S; Melbø-Jørgensen C; Patel HR; Dønnem T; Busund LT; Bremnes RM
Prostate; 2015 Nov; 75(15):1682-93. PubMed ID: 26268996
[TBL] [Abstract][Full Text] [Related]
64. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.
Schoppmann SF; Birner P; Stöckl J; Kalt R; Ullrich R; Caucig C; Kriehuber E; Nagy K; Alitalo K; Kerjaschki D
Am J Pathol; 2002 Sep; 161(3):947-56. PubMed ID: 12213723
[TBL] [Abstract][Full Text] [Related]
65. [Correlation of lymphangiogenesis to progression of colorectal cancer].
Wang TB; Huang YH; Lan P; Song XM; Wang JP
Ai Zheng; 2005 Oct; 24(10):1276-9. PubMed ID: 16219148
[TBL] [Abstract][Full Text] [Related]
66. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia.
Gebhardt M; Mentlein R; Schaudig U; Pufe T; Recker K; Nölle B; Al-Samir K; Geerling G; Paulsen FP
Ophthalmology; 2005 Jun; 112(6):1023-30. PubMed ID: 15885787
[TBL] [Abstract][Full Text] [Related]
67. The relevance of cell type- and tumor zone-specific VEGFR-2 activation in locally advanced colon cancer.
Jayasinghe C; Simiantonaki N; Habedank S; Kirkpatrick CJ
J Exp Clin Cancer Res; 2015 May; 34(1):42. PubMed ID: 25967108
[TBL] [Abstract][Full Text] [Related]
68. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
69. Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor.
Suganuma T; Ino K; Shibata K; Nomura S; Kajiyama H; Kikkawa F; Tsuruoka N; Mizutani S
Lab Invest; 2004 May; 84(5):639-48. PubMed ID: 15048132
[TBL] [Abstract][Full Text] [Related]
70. Analysis of systemic inflammatory response in the carcinogenic process of uterine cervical neoplasia.
Lages EL; Belo AV; Andrade SP; Rocha MÂ; de Freitas GF; Lamaita RM; Traiman P; Silva-Filho AL
Biomed Pharmacother; 2011 Oct; 65(7):496-9. PubMed ID: 22004597
[TBL] [Abstract][Full Text] [Related]
71. Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer.
Kuemmel S; Thomas A; Landt S; Fuger A; Schmid P; Kriner M; Blohmer JU; Sehouli J; Schaller G; Lichtenegger W; Köninger A; Fuchs I
Anticancer Res; 2009 Feb; 29(2):641-5. PubMed ID: 19331214
[TBL] [Abstract][Full Text] [Related]
72. Tissue expression of VEGF in cervical intraepithelial neoplasia and cervical cancer.
Mandic A; Usaj Knezevic S; Kapicl Ivkovic T
J BUON; 2014; 19(4):958-64. PubMed ID: 25536602
[TBL] [Abstract][Full Text] [Related]
73. Multidimensional outlook on the pathophysiology of cervical cancer invasion and metastasis.
George N; Bhandari P; Shruptha P; Jayaram P; Chaudhari S; Satyamoorthy K
Mol Cell Biochem; 2023 Nov; 478(11):2581-2606. PubMed ID: 36905477
[TBL] [Abstract][Full Text] [Related]
74. Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.
Mahnashi MH; El-Senduny FF; Alshahrani MA; Abou-Salim MA
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215358
[TBL] [Abstract][Full Text] [Related]
75. VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.
Jung O; Beauvais DM; Adams KM; Rapraeger AC
J Cell Sci; 2019 Oct; 132(20):. PubMed ID: 31562188
[TBL] [Abstract][Full Text] [Related]
76. High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer.
Dang YZ; Zhang Y; Li JP; Hu J; Li WW; Li P; Wei LC; Shi M
Medicine (Baltimore); 2017 Jan; 96(1):e5772. PubMed ID: 28072723
[TBL] [Abstract][Full Text] [Related]
77. Immunohistochemical Expression of VEGF and Podoplanin in Uterine Cervical Squamous Intraepithelial Lesions.
Belfort-Mattos PN; Focchi GR; Ribalta JC; Megale De Lima T; Nogueira Carvalho CR; Kesselring Tso F; De Góis Speck NM
Dis Markers; 2016; 2016():8293196. PubMed ID: 27313335
[TBL] [Abstract][Full Text] [Related]
78. Lymphangiogenesis in cervical cancer evaluated by expression of the VEGF-C gene in clinical stage IB-IIIB.
Franc M; Kachel-Flis A; Michalski B; Fila-Daniłow A; Mazurek U; Michalski M; Michalska A; Kuczerawy I; Skrzypulec-Plinta V
Prz Menopauzalny; 2015 Jun; 14(2):112-7. PubMed ID: 26327898
[TBL] [Abstract][Full Text] [Related]
79. Expression of VEGF, VEGF-C and VEGFR-2 in in situ and invasive SCC of cervix.
Jach R; Dulinska-Litewka J; Laidler P; Szczudrawa A; Kopera A; Szczudlik L; Pawlik M; Zajac K; Mak M; Basta A
Front Biosci (Elite Ed); 2010 Jan; 2(2):411-23. PubMed ID: 20036889
[TBL] [Abstract][Full Text] [Related]
80. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis.
Van Trappen PO; Steele D; Lowe DG; Baithun S; Beasley N; Thiele W; Weich H; Krishnan J; Shepherd JH; Pepper MS; Jackson DG; Sleeman JP; Jacobs IJ
J Pathol; 2003 Dec; 201(4):544-54. PubMed ID: 14648657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
